- Home
- AKBA
as 07-26-2024 4:00pm EST
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 190.7M | IPO Year: | 2014 |
| Target Price: | $5.00 | AVG Volume (30 days): | 3.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.78 - $2.48 | Next Earning Date: | 08-23-2024 |
| Revenue: | $187,225,000 | Revenue Growth: | -30.88% |
| Revenue Growth (this year): | -9.57% | Revenue Growth (next year): | -7.63% |
Stock Insider Trading Activity of Akebia Therapeutics Inc. (AKBA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hadas Nicole R. | AKBA | SVP, Chief Legal Officer | May 13 '24 | Sell | $1.26 | 12,016 | $15,140.16 | 651,243 | SEC Form 4 |
| Dahan Michel | AKBA | SVP, Chief Operating Officer | May 13 '24 | Sell | $1.26 | 34,840 | $43,898.40 | 672,092 | SEC Form 4 |
| Hadas Nicole R. | AKBA | SVP, Chief Legal Officer | Feb 29 '24 | Sell | $1.58 | 5,974 | $9,438.92 | 663,259 | SEC Form 4 |
| Butler John P. | AKBA | CEO and President | Feb 29 '24 | Sell | $1.58 | 46,570 | $73,580.60 | 2,044,580 | SEC Form 4 |
| Burke Steven Keith | AKBA | SVP, Chief Medical Officer | Feb 29 '24 | Sell | $1.58 | 7,169 | $11,327.02 | 695,840 | SEC Form 4 |
| Dahan Michel | AKBA | SVP, Chief Operating Officer | Feb 29 '24 | Sell | $1.58 | 8,661 | $13,684.38 | 706,932 | SEC Form 4 |
| Burke Steven Keith | AKBA | SVP, Chief Medical Officer | Feb 27 '24 | Sell | $1.52 | 8,367 | $12,717.84 | 703,009 | SEC Form 4 |
| Dahan Michel | AKBA | SVP, Chief Operating Officer | Feb 27 '24 | Sell | $1.52 | 10,744 | $16,330.88 | 715,593 | SEC Form 4 |
| Hadas Nicole R. | AKBA | SVP, Chief Legal Officer | Feb 27 '24 | Sell | $1.52 | 7,411 | $11,264.72 | 669,233 | SEC Form 4 |
| Butler John P. | AKBA | CEO and President | Feb 27 '24 | Sell | $1.52 | 37,733 | $57,354.16 | 2,091,150 | SEC Form 4 |
| Butler John P. | AKBA | CEO and President | Jan 31 '24 | Sell | $1.68 | 46,489 | $78,101.52 | 2,128,883 | SEC Form 4 |
| Burke Steven Keith | AKBA | SVP, Chief Medical Officer | Jan 31 '24 | Sell | $1.68 | 24,311 | $40,842.48 | 711,376 | SEC Form 4 |
| Burke Steven Keith | AKBA | SVP, Chief Medical Officer | Aug 25 '23 | Sell | $1.15 | 27,000 | $31,050.00 | 668,840 | SEC Form 4 |
Latest Akebia Therapeutics Inc. News
AKBA Breaking Stock News: Dive into AKBA Ticker-Specific Updates for Smart Investing
MT Newswires
15 days ago
Akebia Regains Full Rights to Sell Vafseo Tablets in US After Ending Licensing Deal With CSL Vifor
PR Newswire
16 days ago
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets
PR Newswire
25 days ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
a month ago
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
MT Newswires
a month ago
Akebia Therapeutics Names Erik Ostrowski CFO, CBO
PR Newswire
a month ago
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
Simply Wall St.
a month ago
Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%
ACCESSWIRE
2 months ago
Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge
Compare AKBA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKBA Akebia Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.